Wrinkles Clinical Trial
Official title:
A Prospective, Randomized, Multi-Center, Subject- and Evaluator-Blinded, Parallel Comparison of Dysport®, When Reconstituted at 1.5 mL and 2.5 mL, for the Treatment of Moderate to Severe Glabellar Lines.
Verified date | September 2018 |
Source | Galderma R&D |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is designed to evaluate the safety, efficacy, and subject and investigator satisfaction of 2 different injection volumes of Dysport in the glabellar lines. 1. To determine the proportion of composite responders (based on blinded evaluator and subject assessments) who achieve at least a 1-point reduction from baseline in glabellar line severity score (GLSS) at maximum frown line on Day 30. 2. To assess the GLSS, at maximum frown and at rest, by live assessment at all visits. 3. To evaluate the onset of effect on appearance of glabellar lines starting at the Day 2 visit (subject and blinded evaluator). 4. To assess the subject's satisfaction with the treatment. 5. To evaluate investigator satisfaction of treatment outcome. 6. To evaluate subject psychological well-being. 7. To evaluate subject age appraisal. 8. To evaluate all adverse events during the course of the study.
Status | Completed |
Enrollment | 60 |
Est. completion date | October 2016 |
Est. primary completion date | October 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 64 Years |
Eligibility | Key Inclusion Criteria: 1. Botulinum toxin naïve subject (facial area) 2. Moderate to severe (GLSS = 2 or 3) glabellar lines at maximum frown and mild to severe (GLSS = 1, 2, or 3) glabellar lines at rest using the validated 4-point Photographic Scale, as assessed by the treating investigator and the blinded evaluator. Key Exclusion Criteria: 1. Have known allergies or sensitivities to Dysport®, any of its excipients, or cow's milk protein 2. Have rhytids of the glabellar region that cannot be smoothed out by manually spreading the skin apart 3. Have a history or have signs and symptoms of eyelid or brow ptosis or signs of compensatory frontalis muscle activity, as judged by the investigator 4. Have clinical or subclinical neuromuscular junctional disorders (eg, myasthenia gravis, Lambert Eaton syndrome, or amyotrophic lateral sclerosis) or a history of dysphagia or aspiration 5. Are women who are pregnant or breast-feeding or who intend to get pregnant within the duration of the study 6. Have an active inflammation or infection in the areas to be treated or had any prior surgery, tattoos, piercings, or scarring in the facial area that, in the opinion of the investigator, may interfere with the results 7. Have had any previous insertion of any permanent or semi-permanent material, hyaluronic acid, or collagen fillers in the glabellar region 8. Have any chronic or acute medical condition that, may pose a risk to the safety of the subject, or may interfere with the assessment of safety or efficacy in this study |
Country | Name | City | State |
---|---|---|---|
United States | Skin Research Institute | Coral Gables | Florida |
United States | AboutSkin Dermatology and DermSurgery | Greenwood Village | Colorado |
United States | Marina Peredo, MD, PC | Smithtown | New York |
Lead Sponsor | Collaborator |
---|---|
Galderma R&D |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of Composite Responders Who Achieve at Least a 1-point Reduction From Baseline in Glabellar Line Severity Score (GLSS) at Maximum Frown. | Proportion of composite responders who achieve at least a 1-point reduction from baseline in glabellar line severity score (GLSS) based on subject and blinded-evaluator assessment of glabellar line severity at maximum frown on Day 30. | 30 days | |
Secondary | Proportion of Responders, at Maximum Frown (Subject) | Proportion of responders, at maximum frown, with GLSS at least 1-point reduction from baseline on days 2, 3, 4, 7, 14, 30, 90 and 120 based on assessments by subject using a static 4-point categorical (subject) scale. | 120 days | |
Secondary | Proportion of Responders, at Maximum Frown (Blinded Evaluator) | Proportion of responders, at maximum frown, with GLSS at least 1-point reduction from baseline on days 2, 3, 4, 7, 14, 30, 90 and 120 based on assessments by blinded evaluator using a validated 4-point photographic scale. | 120 days | |
Secondary | Proportion of Responders, at Maximum Frown (Treating Investigator) | Proportion of responders, at maximum frown, with GLSS at least 1-point reduction from baseline on days 2, 3, 4, 7, 14, 30, 90 and 120 based on assessments by treating investigator using a validated 4-point photographic scale. | 120 days | |
Secondary | Proportion of Combination Responders, at Maximum Frown (Blinded Evaluator and Subject) | Proportion of combination responders, at maximum frown, with GLSS at least 1-point reduction from baseline on days 2, 3, 4, 7, 14, 30, 90 and 120 based on assessments made by blinded evaluator and subject. | 120 days | |
Secondary | Proportion of Responders, at Rest (Subject) | Proportion of responders, at rest, with GLSS at least 1-point reduction from baseline on days 2, 3, 4, 7, 14, 30, 90 and 120 based on assessments made by subject using a static 4-point categorical (subject) scale. | 120 days | |
Secondary | Proportion of Responders, at Rest (Blinded Evaluator) | Proportion of responders, at rest, with GLSS at least 1-point reduction from baseline on days 2, 3, 4, 7, 14, 30, 90 and 120 based on assessments made by blinded evaluator using a validated 4-point photographic scale. | 120 days | |
Secondary | Proportion of Responders, at Rest (Treating Investigator) | Proportion of combination responders, at rest, with GLSS at least 1-point reduction from baseline on days 2, 3, 4, 7, 14, 30, 90 and 120 based on assessments made by treating investigator using a validated 4-point photographic scale. | 120 days | |
Secondary | Proportion of Combination Responders, at Rest (Blinded Evaluator and Subject) | Proportion of combination responders, at rest, with GLSS at least 1-point reduction from baseline on days 2, 3, 4, 7, 14, 30, 90 and 120 based on assessments made by blinded evaluator and subject. | 120 days | |
Secondary | Proportion of Subjects Who Achieved an Onset of Effect on the Appearance of the Subject's Glabellar Lines. | Combination endpoint from both subject and blinded evaluator assessments. Assessments made on days 2, 3, 4, and 7. | 7 days | |
Secondary | Subject Satisfaction With the Treatment of Glabellar Lines - I am Satisfied With How I Look. | Proportion of subjects who responded 'agree' or 'strongly agree' regarding change from baseline in subject satisfaction questionnaire on day 120. | 120 days | |
Secondary | Investigator Satisfaction With Treatment Outcome - Satisfied With the Study Product Results | Proportion of treating investigators who responded 'agree' or 'strongly agree' to the individual satisfaction questions on Day 30. | 30 days | |
Secondary | Subject Psychological Well-being - Mean Change at Day 120 Compared to Baseline | Mean change from baseline on day 120 using the Psychological Well-Being (FACE-Q).Total score for entire questionnaire is transformed to a Rasch score, scale of 0-100. Increase in score = increased well-being. |
Baseline and Day 120 | |
Secondary | Subject Age Appraisal Using the FACE-Q-Age Appraisal Visual Analog Scale (VAS) - Mean Change at Day 120 Compared to Baseline | Mean change from baseline on day 120 using the FACE-Q Age Appraisal VAS. "0" years represents "current age subjects rated their appearance as older or younger than current age"; "+" years represents "older than current age"; "-" years represents "younger than current age". | Baseline and Day 120 | |
Secondary | Subject Appraisal of Lines Between the Eyebrows (FACE-Q) - Mean Change at Day 120 Compared to Baseline | Mean change from baseline on day 120 using the Subject Appraisal Lines Between the Eyebrows (FACE-Q).Total score for entire questionnaire is transformed to a Rasch score, scale of 0-100. Increase in score = less bothered by glabellar lines. | Baseline and Day 120 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01984619 -
Prospective Study Evaluating the Treatment of Hyperdynamic Forehead Wrinkles
|
N/A | |
Completed |
NCT01713985 -
Feasibility Study: Evaluation of Ulthera Versus Thermage for Treating the Face and Neck
|
N/A | |
Recruiting |
NCT01586819 -
Lateral Canthal Rhytides With Medium Depth Chemical Peel With or Without Pretreatment With Botulinum Toxin A
|
Phase 3 | |
Completed |
NCT05254210 -
Feasibility Study To Collect Safety And Preliminary Efficacy Data For A Radiofrequency Microneedling Device
|
N/A | |
Completed |
NCT02604641 -
Assessment of the Impact of a Coenzyme Q10 Supplementation on the Skin
|
N/A | |
Completed |
NCT01460927 -
TriActive+ Radiofrequency (RF) for Non-invasive Treatment of Wrinkles & Rhytides
|
N/A | |
Completed |
NCT01519934 -
A Retrospective Study to Evaluate the Effectiveness of the Ulthera System
|
N/A | |
Completed |
NCT03811756 -
The Effect of 12-week Dietary Intake of Syrup Containing CoQ10 and Collagen on Dermis Density and Other Skin Parameters
|
N/A | |
Completed |
NCT04988412 -
The Effect of 12-week Dietary Intake of Food Supplements Containing Collagen on Dermis Density and Other Skin Parameters
|
N/A | |
Completed |
NCT02913547 -
Silk'n HST for Wrinkle Reduction - Clinical Study Protocol
|
N/A | |
Active, not recruiting |
NCT02019004 -
A Pilot Study Testing Onabotulinum Toxin A Versus Incobotulinum Toxin A Injections for Facial Wrinkles
|
N/A | |
Completed |
NCT02340078 -
A Clinical Study to Evaluate the Efficacy and Safety of YVOIRE Volume Plus Versus YVOIRE Volume in Nasolabial Fold Injection
|
N/A | |
Completed |
NCT01283464 -
Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles
|
Phase 2 | |
Completed |
NCT01034956 -
Outcomes and Patient Experience After Soft Tissue Dermal Filler Injections
|
N/A | |
Completed |
NCT02425943 -
Sculptra Aesthetic Post-Approval Study
|
Phase 4 | |
Recruiting |
NCT05847530 -
Pilot Evaluation of the Cynosure Potenza™ System for Treatment of Cosmetic Dermatologic Skin Conditions
|
N/A | |
Enrolling by invitation |
NCT01847066 -
Epidermal Delivery of Ani-Aging Ingredients
|
N/A | |
Completed |
NCT01859611 -
TriActive+ Radiofrequency (RF) for Non-Invasive Treatment of Wrinkles and Rhytides
|
N/A | |
Completed |
NCT01297634 -
Radial Diffusion of the Botulinum Toxin Type A (Botox®): Electromyographic Evaluation of the Frontal Muscle
|
Phase 4 | |
Completed |
NCT05011461 -
The Effect of Topical Almond Oil vs. Topical Retinol on The Appearance of Facial Wrinkles
|
N/A |